PapersPMID:28940986
Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis.
What moved
1 findingHow to read these marks →- Increases patient survival rate
moderate
“There was s significant increase of survival rate in lentinan group compared with control in 1 year [RR, 1.46, 95% CI (1.16–1.84); P = 0.001], whereas no significant difference was found in 2 years [1.16 (0.85–1.56); P = 0.34]; as shown in Figure 3.”
- Study
- meta-analysis
- Effect
- 1.46 risk ratio, 95% CI 1.16 to 1.84
- Dose studied
- 1 mg or 2 mg per injection, from once daily to twice a month across trials
- Population
- Patients with advanced solid tumours in pooled trials, lentinan added to chemotherapy versus chemotherapy alone; 1-year survival
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients with advanced gastrointestinal, lung, hepatocellular or esophageal cancer given chemotherapy with or without lentinan
- Participants
- 1,423
- Comparator
- an active treatment / no treatment
- Duration
- not reported
- Endpoints measured
- 37